West Virginia 5-FU and Xeloda Overdose and Toxicity Claims

Suspected chemotherapy overdose or rapidly worsening toxicity is a medical emergency. Contact the treating oncology team and seek emergency care immediately. Do not delay medical treatment while seeking legal advice.

An infusion pump that empties much earlier than scheduled, unexpectedly severe symptoms during the first days of treatment, or a rapid decline after taking Xeloda or receiving 5-FU may signal an overdose or early-onset toxicity. A true overdose can result from a dosage, pharmacy, or infusion-pump error. Severe toxicity can also occur after a prescribed dose when the patient cannot adequately break down the medication. A malpractice claim may exist when a provider fails to use appropriate precautions, recognize urgent warning signs, or provide timely emergency treatment, and that failure causes additional injury or death.

What Are 5-FU, Capecitabine, and Xeloda?

Fluorouracil, commonly called 5-FU, is an intravenous chemotherapy medication that may be delivered through an infusion pump over a specified number of hours. Xeloda is the brand name for capecitabine, an oral medication the body converts into 5-FU. Both are fluoropyrimidines.

A true overdose may involve the wrong dose, a compounding or calculation error, incorrect pump programming, delivery at an excessive rate, or a failure to investigate a pump that empties too quickly. A separate problem arises when a patient develops severe toxicity from the prescribed dose, including because of partial or complete DPD deficiency.

DPYD Variants and DPD Deficiency

The DPYD gene provides instructions for producing dihydropyrimidine dehydrogenase, or DPD, an enzyme that breaks down most fluorouracil in the body. Certain DPYD variants can cause partial or complete DPD deficiency, allowing 5-FU or capecitabine to accumulate to dangerous levels even when the prescribed dosage was not excessive.

Current FDA labeling advises DPYD testing before capecitabine or 5-FU unless immediate treatment is necessary. It advises avoiding these medications in patients with certain variants associated with complete DPD deficiency and individualizing treatment for partial deficiency. Testing is not perfect, and serious toxicity can occur even when no tested variant is found. Whether testing should have been performed in a particular case depends on the treatment date, urgency, available information, and expert review.

Vistogard for 5-FU and Capecitabine Emergencies

Vistogard (uridine triacetate) is approved for emergency treatment following a fluorouracil or capecitabine overdose and for certain early-onset, severe, or life-threatening toxicity occurring within 96 hours after administration. The prescribing information directs that it be given as soon as possible and states that safety and efficacy when treatment begins more than 96 hours later have not been established.

The timeline is therefore critical: when the infusion or last oral dose ended, when symptoms began, when the patient first reported them, when an overdose or severe toxicity was recognized, and when Vistogard was considered, obtained, or administered.

Warning Signs of Severe Fluoropyrimidine Toxicity

Common chemotherapy side effects do not necessarily establish an overdose. Symptoms that appear unusually early, worsen rapidly, or are substantially more severe than expected nevertheless require prompt evaluation. Warning signs may include:

• An infusion pump becoming empty much earlier than scheduled;
• Severe diarrhea, vomiting, dehydration, or inability to retain fluids;
• Painful mouth or throat sores, swelling, or difficulty swallowing;
• Fever, chills, unusual bleeding, or other signs of serious infection;
• Severe weakness, dizziness, confusion, poor coordination, or other neurologic changes; and
• Chest pain, shortness of breath, fainting, or a rapid overall decline.

These symptoms should be reported immediately to the treating medical team and evaluated as a medical—not merely a legal—emergency.

West Virginia Lawsuits Alleging Chemotherapy Overdose or Toxicity

The following summaries describe allegations in civil complaints. A complaint states one party’s allegations and is not a judicial finding of negligence or legal responsibility.

Phelps v. Charleston Area Medical Center, Inc.—Alleged Xeloda Toxicity

A complaint filed in Kanawha County Circuit Court in 2026 alleges that Rose Marie Phelps developed severe, early-onset toxicity after beginning Xeloda for anal cancer. The complaint alleges that providers failed to adequately warn her about DPD deficiency, recognize escalating symptoms, and provide Vistogard in a timely manner.

According to the complaint, later testing identified DPYD variants associated with impaired metabolism of Xeloda. Mrs. Phelps ultimately received Vistogard after a substantial delay and died on August 31, 2025. David B. Phelps Sr., as personal representative of her estate, alleges professional and institutional negligence and wrongful death. Attorneys with Hendrickson & Long, PLLC are among the counsel representing him. Liability has not been adjudicated. Read the filed complaint.

Milam Complaint—Alleged 5-FU Infusion Overdose

In a separate West Virginia matter, an amended complaint alleges that Mr. Milam was sent home with an infusion pump intended to deliver 5-FU over approximately 46 hours, but the medication was delivered in about five hours. It further alleges that he reported the unexpectedly rapid infusion when the pump was disconnected on January 6, 2023, but the information was not promptly escalated to a physician or otherwise acted upon.

According to the complaint, Mr. Milam later returned with weakness, dizziness, severe burning pain, and difficulty swallowing. The estate alleges that the overdose was not recognized and addressed in time for Vistogard to be initiated within the period addressed by its labeling. His condition deteriorated, and he died on January 13, 2023. The estate alleges medical malpractice and wrongful death; those allegations have not been adjudicated.

 

When May Medical Malpractice Be Involved?

Depending on the circumstances, a chemotherapy overdose or toxicity claim may involve:

• Prescribing, preparing, or administering the wrong drug or dosage;
• Incorrectly programming or setting up an infusion pump;
• Failing to investigate a pump that emptied too quickly;
• Failing to consider DPYD testing when indicated by the standards applicable at the time;
• Failing to recognize or act on unexpectedly early or severe toxicity; or
• Delaying communication, escalation of care, or consideration and acquisition of Vistogard.

A poor outcome alone does not establish malpractice. Qualified medical experts generally must determine the applicable standard of care, whether it was violated, and whether the violation caused or worsened the injury.

Legal Rights and Important Evidence

These cases often depend on an exact treatment timeline. Patients and families should preserve medication bottles and packaging, treatment schedules, pump identifying information, photographs, portal messages, call histories, and discharge instructions. Relevant medical evidence may include chemotherapy orders, pharmacy and administration records, pump data, laboratory results, DPYD testing, and records showing when Vistogard was considered or administered.

A seriously injured patient may have a West Virginia medical professional liability claim. When the patient dies, West Virginia law generally requires the wrongful-death action to be brought by the duly appointed personal representative. Before filing most medical professional liability actions, a claimant generally must provide presuit notice and a screening certificate of merit, subject to statutory exceptions.

These claims are deadline-sensitive. West Virginia law generally provides a two-year limitations period measured from the injury or death or from when the medical injury was or reasonably should have been discovered, whichever last occurs, together with a 10-year outer limitation and specified exceptions. The precise deadline depends on the facts, and the expert-review and presuit process takes time.

Hendrickson & Long, PLLC, Can Help

Chemotherapy-overdose and severe-toxicity cases require careful review of oncology, pharmacy, nursing, genetic-testing, emergency-treatment, and causation issues. Attorneys with Hendrickson & Long, PLLC currently represent the Phelps estate in litigation alleging delayed recognition and treatment of severe Xeloda toxicity. We can obtain the records, reconstruct the timeline, preserve evidence, consult qualified experts, and explain the available legal options. Learn more about the Phelps case.

If you believe you or a loved one suffered serious harm because of a chemotherapy overdose, medication error, or delayed treatment, contact Hendrickson & Long, PLLC to discuss your situation. You may also contact Raj Shah, Jack Tinney, or John Cecil directly.

Call 304-346-5500 for a free and confidential consultation.

An ongoing representation or prior result does not guarantee the outcome of another matter.

Frequently Asked Questions About 5-FU and Xeloda Toxicity

Is severe 5-FU or Xeloda toxicity the same as an overdose?

Not necessarily. An overdose means that too much medication was delivered or it was delivered too quickly. Severe toxicity can also occur after a prescribed dose when the patient cannot adequately metabolize the drug, including because of partial or complete DPD deficiency.

Should I have been tested for a DPYD variant before treatment?

Current FDA labeling advises DPYD testing before capecitabine or 5-FU unless immediate treatment is necessary. Available tests have limitations, and whether testing should have occurred in a particular case depends partly on the treatment date and applicable standards. Failure to test does not automatically establish malpractice.

What is the 96-hour period associated with Vistogard?

Vistogard should be administered as soon as possible after a qualifying overdose or early-onset toxicity. Its labeling addresses toxicity occurring within 96 hours and states that safety and efficacy when treatment begins more than 96 hours after administration have not been established.

Can there be a claim even if the prescribed dosage was correct?

Potentially. A claim may concern a failure to evaluate known risks, recognize unusually early or severe toxicity, act on abnormal results, escalate care, or timely consider emergency treatment. Whether those events constitute malpractice requires expert review.

How long do I have to investigate a potential claim?

Medical-malpractice and wrongful-death claims are subject to strict and sometimes overlapping deadlines. Although two years is the general starting point for many West Virginia claims, the discovery rule, date of death, statutory repose period, and other circumstances can affect the analysis. Prompt consultation is important.